Glyxambi, a medication combining empagliflozin and linagliptin used to manage type 2 diabetes, is not currently approved or marketed in Egypt [1]. Therefore, there is no established price for Glyxambi in Egypt.
When might Glyxambi become available in Egypt?
The availability of Glyxambi in Egypt depends on regulatory approval processes. Companies must submit applications to the Egyptian Drug Authority for review and authorization before a medication can be marketed. The timeline for such approvals can vary significantly [1].
What are the active ingredients in Glyxambi?
Glyxambi contains two active pharmaceutical ingredients: empagliflozin and linagliptin [1]. Empagliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors, while linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor [1].
How do empagliflozin and linagliptin work together?
The combination of empagliflozin and linagliptin in Glyxambi targets type 2 diabetes through complementary mechanisms. Empagliflozin works by increasing the amount of glucose excreted in the urine, thereby lowering blood glucose levels [1]. Linagliptin works by increasing the levels of incretin hormones, which help to reduce glucose production by the liver and increase insulin secretion from the pancreas [1]. This dual action helps to improve glycemic control [1].
What is the typical price of Glyxambi in countries where it is available?
In countries where Glyxambi is approved and available, such as the United States, the price can vary. Factors influencing the cost include insurance coverage, pharmacy pricing, and available discounts or patient assistance programs [2]. For example, without insurance, a 30-day supply could range from several hundred dollars [2].
Are there alternative medications for type 2 diabetes available in Egypt?
Yes, numerous alternative medications for managing type 2 diabetes are available in Egypt. These may include other SGLT2 inhibitors, DPP-4 inhibitors, metformin, sulfonylureas, and insulin, among others. The choice of alternative depends on individual patient needs, glycemic control goals, and physician recommendations [1].